Study in Patients With Knee Osteoarthritis Treated by Embolization Using NBGM200

NCT ID: NCT06930677

Last Updated: 2025-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-17

Study Completion Date

2027-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study in patients with knee osteoarthritis treated by embolization using NBGM200

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Osteoarthritis (Knee OA)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MSK embolization

Group Type EXPERIMENTAL

embolization therapy

Intervention Type DEVICE

MSK embolization

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

embolization therapy

MSK embolization

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Osteoarthritis proven by MR-imaging

Exclusion Criteria

* Current local infection
* Life expectancy less than 6 months
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Next Biomedical Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Ghent

Ghent, , Belgium

Site Status RECRUITING

Uz Leuven

Leuven, , Belgium

Site Status RECRUITING

Elisabeth-Tweesteden Hospital

Tilburg, , Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium Netherlands

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

University Hospital Ghent

Role: primary

09 332 21 11

UZ LEUVEN

Role: primary

+32 16 33 22 11

Paul N. M. Lohle

Role: primary

+31 13 221 0000

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GENTILLE

Identifier Type: OTHER

Identifier Source: secondary_id

TAME 003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bayer OA Knee Pain Pilot
NCT05349682 RECRUITING NA